CIK 0000818033
- Accelerated filer
HERON THERAPEUTICS, INC. /DE/
Sign in to watch- Ticker
- HRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 942875566
- Phone
- +1 858-251-4400
- Business address
- 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- AP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-12-12 | Gelder Mark S. MD SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2014-12-12 | Drazba Brian G. VP, Finance & CFO | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2014-12-12 | POYHONEN JOHN Director | Grant or award · Stock Option (Right to Buy) | +19,500 | 19,500 | ||
| 2014-12-12 | MANHARD KIMBERLY Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2014-12-12 | Johnson Craig A Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2014-12-12 | DAVIS STEPHEN Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2014-10-31 | Quart Barry D Chief Executive Officer | Other acquisition | +1,941 | $7.50 | $15K | 63,796 |
| 2014-10-31 | Drazba Brian G. VP, Finance & CFO | Other acquisition | +818 | $7.50 | $6K | 818 |
| 2014-09-26 | DAVIS STEPHEN Director | Exercise or conversion | +120,313 | $7.20 | $866K | 122,710 |
| 2014-09-26 | DAVIS STEPHEN Director | Shares withheld for taxes | −102,634 | $8.44 | $866K | 20,076 |
| 2014-09-26 | DAVIS STEPHEN Director | Exercise or conversion · Stock Option (Right to Buy) | −120,313 | 0 | ||
| 2014-09-03 | DAVIS STEPHEN Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2014-06-25 | TANG KEVIN C Director | Purchase | +510,638 | $11.75 | $6.0M | 4,596,318 |
| 2014-06-25 | Quart Barry D Chief Executive Officer | Purchase | +10,000 | $11.75 | $118K | 61,855 |
| 2014-03-18 | Gelder Mark S. MD SVP & Chief Medical Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2014-01-10 | TANG KEVIN C Director | Grant or award · Stock Option (right to buy) | +29,500 | 29,500 | ||
| 2014-01-10 | TANG KEVIN C Director | Grant or award · Stock Option (right to buy) | +27,750 | 27,750 | ||
| 2014-01-03 | Quart Barry D Chief Executive Officer | Grant or award · Stock Option (right to buy) | −2,733,333 | 2,733,333 | ||
| 2014-01-03 | Rosen Robert President | Grant or award · Stock Option (right to buy) | +3,400,000 | 3,400,000 | ||
| 2014-01-03 | Gelder Mark S. MD SVP & Chief Medical Officer | Grant or award · Stock Option (right to buy) | +1,600,000 | 1,600,000 |
Page 39 of 45 · 881 trades